A community portal about Irritable bowel syndrome with blogs, videos, and photos. According to Wikipedia.org: In gastroenterology, irritable bowel syndrome or spastic colon is a functional bowel disorder characterized by abdominal pain...
[more]
A community portal about Irritable bowel syndrome with blogs, videos, and photos. According to Wikipedia.org: In gastroenterology, irritable bowel syndrome or spastic colon is a functional bowel disorder characterized by abdominal pain and changes in bowel habits which are not associated with any abnormalities seen on routine clinical testing. It is fairly common and makes up 20–50% of visits to gastroenterologists. Lower abdominal pain, and bloating associated with alteration of bowel habits and abdominal discomfort relieved with defecation are the most frequent symptoms. The abdominal pain type is usually described in a patient as either diarrhea -predominant, constipation -predominant or IBS with alternating stool pattern. In some individuals, IBS may have an acute onset and develop after an infectious illness characterised by two or more of the following: fever, vomiting, acute diarrhea, positive stool culture. This post-infective syndrome has consequently been termed "post-infectious IBS" and is acute onset Rome II criteria positive. This condition is more homogenous, being mostly IBS-D and is drawing much clinical investigation.
http://www.companiesandmarkets.com/Summary-Market-Report/digestive-system-irritable-bowel-syndrome-therapy-area-pipeline-report-188008.asp
The Irritable Bowel Syndrome Therapy Area Pipeline Report contains detailed information on the allergy drug pipeline. This report provides insight into the pipeline status of irritable bowel syndrome drugs by company and by stage as well as a summary of the latest news and developments in this area.
Scope...
International gastroenterology and microbiology experts were invited by Institut Rosell-Lallemand to share and discuss with representatives from the pharma and health care industry the latest research on probiotics in irritable bowel syndrome (IBS)
Neither ulcerative colitis nor Crohn's disease should be confused with irritable bowel syndrome (IBS), a disorder that affects the ... CCFA's continuing research efforts, much more will be learned and a cure will eventually be found. How Common is ...
THE WOODLANDS, Texas, Nov. 23 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. , announced today that top-line data from its Phase 2 clinical study with LX1031 in patients with non-constipating irritable bowel syndrome (IBS) will be presented at GASTRO 2009 in London this week. Results from the study, which showed a significant improvement in IBS symptoms, will be presented...
Valeant Pharma begins selling generic IBS drugThe Associated PressALISO VIEJO, Calif. — Valeant Pharmaceuticals said Monday it began selling a generic version of Librax, a treatment for irritable bowel syndrome drug. ...Valeant Launching Generic Digestive DrugOrange County Business JournalOceanside Pharma Unveils Launch Of Generic Version Of Librax AG - Quick FactsRTT NewsOceanside Pharmaceuticals Announces Launch of Librax(R) AGPR Newswire...
Background:
Functional abdominal pain syndrome (FAPS) has chronic unexplained abdominal pain and is similar to the psychiatric diagnosis of somatoform pain disorder. A patient with irritable bowel syndrome (IBS) also has chronic unexplained abdominal pain, and rectal hypersensitivity is observed in a majority of the patients. However, no reports have evaluated the visceral sensory function of FAPS precisely. We aimed to test the hypothesis...
Ironwood Pharmaceuticals is gearing up for the possibility of an IPO. The Cambridge, MA-based developer of a new treatment for bowel disorders like for irritable bowel syndrome and chronic constipation said it may raise as much as $172.5 million from investors through the deal, according to a prospectus filed late today.
The proposed offering would be [...]
Ironwood Receives $75M from Astellas for IBS DrugOneMedPlace (blog)While it may not be fatal, irritable bowel syndrome (IBS) ranks high in discomfort and embarrassment. The chronic gastrointestinal disorder is characterized ...Astellas Enters Asian Licensing Agreement for Ironwood's Phase III IBS Therapy ...Genetic Engineering News (press release)Almirall announces a US$ 15 M equity investment in Ironwood Pharmaceuticals ...PharmaLive.com...
I have to wear a special absorbent undergarment whenever I leave the house. Two years ago, I had surgery to remove about eight inches of my bowel that had become dilated. My doctor gave me a small printout about IBS. I was told that there is nothing ...
Now, that's irritatingExpress BuzzIrritable bowel syndrome (IBS) is a functional gastrointestinal disorder. Also called spastic colon, it is a functional bowel disorder characterised by ...
Irritable bowel syndrome (IBS) occurs when the intestines squeeze too hard — or not hard enough — as food passes through. Symptoms may include diarrhoea or constipation, bloating, and a feeling that you still need to pass a stool, despite having ...
New research from Nagoya City University in Japan has shown that irritable bowel syndrome (IBS) sufferers could experience significant relief by taking 1g of BioBran, a modified arabinoxylan compound ...
Astellas buys Japan, other rights to new IBS drugReuters... Tuesday it will buy the rights to develop and sell US firm Ironwood Pharmaceuticals' drug for irritable bowel syndrome in Japan and other parts of Asia. ...and more »
ISELIN, N.J., Oct. 21 /PRNewswire-FirstCall/ -- Pharmos Corporation (Pink Sheets: PARS); on September 14, 2009, Pharmos announced the results of its Phase 2b Dextofisopam trial for the treatment of diarrhea predominant and alternating diarrhea and constipation irritable bowel syndrome. While the results did not achieve statistical significance for the primaryread more
CINCINNATI -- Meridian Bioscience Inc. said Wednesday its European business will distribute a test that helps determine the difference between inflammatory bowel disease and irritable bowel syndrome. Meridian Bioscience Europe will distribute the ...